紫杉醇脂质体联合卡铂治疗培美曲塞联合顺铂化疗失败的晚期肺腺癌的临床观察

目的:探讨紫杉醇脂质体联合卡铂治疗培美曲塞联合顺铂化疗失败的晚期肺腺癌的临床疗效及安全性.方法:收集2012年1月至2015年4月22例对培美曲塞联合顺铂方案化疗失败的晚期肺腺癌患者,给予紫杉醇脂质体联合卡铂治疗,具体用药:紫杉醇脂质体175 mg/m2,静脉滴注,第1天;卡铂AUC 5,静脉滴注,第1天,21天为1个周期.至少化疗2个周期后评价疗效及不良反应.结果:全组22例患者均可评价疗效和不良反应.获完全缓解(complete response,CR)0例,部分缓解(partial response,PR)10例,稳定(stable disease,SD)8例,进展(progression disease,PD)4例,有效率(response rate,RR)为45.5%,疾病控制率(disease control rate,DCR)81.8%,中位无进展生存时间(progression free survival,PFS)5.6个月,中位总生存时间(overall survival,OS)9.5个月,1年生存率36.4%.主要不良反应为骨髓抑制,经对症处理后均缓解.结论:紫杉醇脂质体联合卡铂治疗培美曲塞和顺铂化疗失败的晚期肺腺癌疗效较好,不良反应可耐受.

Clinical observation of paclitaxel liposome combined with carboplatin for advanced lung adenocarcinoma patients after the treatment failure of pemetrexed combined with cisplatin

Objective:To investigate efficacy and feasibility of paclitaxel liposome combined with carboplatin for advanced lung adenocarcinoma patients after the treatment failure of pemetrexed and cisplatin.Methods:From January 2012 to April 2015,22 patients with advanced lung adenocarcinoma were enrolled in this study.Paclitaxel liposome was given at a dose 175 mg/m2 intravenous drip,d1,with carboplatin AUC 5 intravenous drip,d1.21 days was a cycle.The efficacy and side effects were evaluated after at least two cycles of chemotherapy.Results:Therapeutic efficacy and adverse reaction could be evaluated in all patients with no CR patient,10 cases of PR,8 cases of SD and 4 cases of PD.The response rate was 45.5%,and the disease control rate was 81.8%.The median progression-free survival and the median overall survival time was 5.6 months and 9.5 months respectively.One-year survival rate was 36.4%.The main side effect was myelosuppression,which was alleviated by symptomatic treatment.Conclusion:Paclitaxel liposome combined with carboplatin for advanced lung adenocarcinoma patients after the treatment failure of pemetrexed combined with cisplatin was effective and well tolerated.